Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

76618

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neurofibromatosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to develop a national service framework for neurofibromatosis Type 1 sufferers.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL960
	answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p> answering member printed Earl Howe grouped question UIN HL961 HL962 question first answered 14/07/2014 16:18:37 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76619

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neurofibromatosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how they will ensure a co-ordinated response at local level for neurofibromatosis Type 1 sufferers.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL961
	answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p> answering member printed Earl Howe grouped question UIN HL960 HL962 question first answered 14/07/2014 16:18:38 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76620

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neurofibromatosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what is the scale of neurofibromatosis Type 1 in the United Kingdom.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL962
	answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p> answering member printed Earl Howe grouped question UIN HL960 HL961 question first answered 14/07/2014 16:18:38 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

65841

	registered interest
	date	03/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pharmaceutical Price Regulation Scheme
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how much rebate they have so far received from pharmaceutical companies under the new Pharmaceutical Price Regulation Scheme agreement.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL833
	answer	answer is ministerial correction date of answer 09/07/2014 answer text <p>The Department has received £74 million from members of the Pharmaceutical Price Regulation Scheme (PPRS) in respect of PPRS payments for the first quarter of the calendar year 2014. The Department intends to publish aggregate information on sales reports and payments made under the scheme on a quarterly basis. The first such publication was made on 30 June and can be found on the Government's website at:</p><p> </p><p>www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information</p><p> </p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the Mandate and as such were included within commissioner allocations.</p><p> </p><p>The Government is committed to improving access to clinically and cost-effective medicines including innovative new medicines. As part of implementing the PPRS, NHS England and the Association of the British Pharmaceutical Industry are discussing how best to improve access to, and optimise patient outcomes from, these medicines.</p> answering member printed Earl Howe grouped question UIN HL834 HL835 question first answered 09/07/2014 15:18:03 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

65842

	registered interest
	date	03/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pharmaceutical Price Regulation Scheme
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether the rebate they receive from pharmaceutical companies under the new Pharmaceutical Price Regulation Scheme agreement will be reallocated as an additional resource to the National Health Service.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL834
	answer	answer is ministerial correction date of answer 09/07/2014 answer text <p>The Department has received £74 million from members of the Pharmaceutical Price Regulation Scheme (PPRS) in respect of PPRS payments for the first quarter of the calendar year 2014. The Department intends to publish aggregate information on sales reports and payments made under the scheme on a quarterly basis. The first such publication was made on 30 June and can be found on the Government's website at:</p><p> </p><p>www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information</p><p> </p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the Mandate and as such were included within commissioner allocations.</p><p> </p><p>The Government is committed to improving access to clinically and cost-effective medicines including innovative new medicines. As part of implementing the PPRS, NHS England and the Association of the British Pharmaceutical Industry are discussing how best to improve access to, and optimise patient outcomes from, these medicines.</p> answering member printed Earl Howe grouped question UIN HL833 HL835 question first answered 09/07/2014 15:18:04 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

65843

	registered interest
	date	03/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pharmaceutical Price Regulation Scheme
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government to what extent they propose to use the rebate they expect to receive from pharmaceutical companies under the new Pharmaceutical Price Regulation Scheme agreement to invest in innovative new medicines and procedures.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL835
	answer	answer is ministerial correction date of answer 09/07/2014 answer text <p>The Department has received £74 million from members of the Pharmaceutical Price Regulation Scheme (PPRS) in respect of PPRS payments for the first quarter of the calendar year 2014. The Department intends to publish aggregate information on sales reports and payments made under the scheme on a quarterly basis. The first such publication was made on 30 June and can be found on the Government's website at:</p><p> </p><p>www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information</p><p> </p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the Mandate and as such were included within commissioner allocations.</p><p> </p><p>The Government is committed to improving access to clinically and cost-effective medicines including innovative new medicines. As part of implementing the PPRS, NHS England and the Association of the British Pharmaceutical Industry are discussing how best to improve access to, and optimise patient outcomes from, these medicines.</p> answering member printed Earl Howe grouped question UIN HL833 HL834 question first answered 09/07/2014 15:18:04 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

61926

	registered interest
	date	16/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mid Staffordshire NHS Foundation Trust
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what is the detailed breakdown of the £7,250,000 so far incurred by the special administration process in relation to Mid Staffordshire NHS Trust.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL344
	answer	answer is ministerial correction date of answer 26/06/2014 answer text <p>The £7,250,000 incurred by the special administration process at Mid Staffordshire NHS Trust relates to the period when the trust special administrators (TSAs) were appointed in April 2013, to the point at which the Secretary of State announced his decision to accept the TSAs' proposals in February 2014.</p><p> </p><p>We are informed by Monitor that the total figure of £7,250,000 can be broadly broken down as follows:</p><p>- Cost of the TSAs and supporting team to run the Trust - £2,000,000;</p><p>- Cost of solution development - £3,600,000; and</p><p>- Cost of stakeholder engagement and consultation - £1,650,000.</p><p> </p><p>Monitor has estimated the total cost of the special administration process will be £12 to £15 million. This was first announced as part of its decision to accept the TSAs' final proposals on 16 January 2104 and re-stated in an announcement on 13 March 2014. This includes the £7,250,000 and £250,000 expenses incurred up to the point of the Secretary of State's decision.</p><p> </p><p>The remainder of the estimated total cost consists of costs incurred in the period leading up to the dissolution of the trust. These are the cost of continuing to employ a team to run the trust, and the cost of implementing the recommendations set out in the TSAs' Final Report.</p><p> </p><p>We are also informed by Monitor that an original budget for the remaining costs was agreed at approximately £7,000,000.</p><p> </p><p>That total figure of £7,000,000 can be broadly broken down as follows:</p><p>- Cost of the TSAs and supporting team to run the Trust - £1,500,000;</p><p>- Cost of delivering the transaction - £2,100,000; and</p><p>- Cost of splitting the Trust - £3,400,000.</p><p> </p><p>The team running the trust will be required to remain in place up to the point at which the trust is dissolved.</p> answering member printed Earl Howe grouped question UIN HL345 question first answered 26/06/2014 15:49:22 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

61927

	registered interest
	date	16/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mid Staffordshire NHS Foundation Trust
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what is the detailed breakdown of the estimated £12 to £15 million total cost of the special administration process in relation to Mid Staffordshire NHS Trust.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL345
	answer	answer is ministerial correction date of answer 26/06/2014 answer text <p>The £7,250,000 incurred by the special administration process at Mid Staffordshire NHS Trust relates to the period when the trust special administrators (TSAs) were appointed in April 2013, to the point at which the Secretary of State announced his decision to accept the TSAs' proposals in February 2014.</p><p> </p><p>We are informed by Monitor that the total figure of £7,250,000 can be broadly broken down as follows:</p><p>- Cost of the TSAs and supporting team to run the Trust - £2,000,000;</p><p>- Cost of solution development - £3,600,000; and</p><p>- Cost of stakeholder engagement and consultation - £1,650,000.</p><p> </p><p>Monitor has estimated the total cost of the special administration process will be £12 to £15 million. This was first announced as part of its decision to accept the TSAs' final proposals on 16 January 2104 and re-stated in an announcement on 13 March 2014. This includes the £7,250,000 and £250,000 expenses incurred up to the point of the Secretary of State's decision.</p><p> </p><p>The remainder of the estimated total cost consists of costs incurred in the period leading up to the dissolution of the trust. These are the cost of continuing to employ a team to run the trust, and the cost of implementing the recommendations set out in the TSAs' Final Report.</p><p> </p><p>We are also informed by Monitor that an original budget for the remaining costs was agreed at approximately £7,000,000.</p><p> </p><p>That total figure of £7,000,000 can be broadly broken down as follows:</p><p>- Cost of the TSAs and supporting team to run the Trust - £1,500,000;</p><p>- Cost of delivering the transaction - £2,100,000; and</p><p>- Cost of splitting the Trust - £3,400,000.</p><p> </p><p>The team running the trust will be required to remain in place up to the point at which the trust is dissolved.</p> answering member printed Earl Howe grouped question UIN HL344 question first answered 26/06/2014 15:49:21 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

61924

	registered interest
	date	16/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Gender Recognition
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what action they have taken to address transgender patient discrimination in the National Health Service.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL342
	answer	answer is ministerial correction date of answer 25/06/2014 answer text <p>We expect people with transgender issues to have the same access to National Health Service treatment, including mental health services, as anybody else in the population. Mental Health has been a priority for this Government for several years now. We made this commitment explicit in the Health and Social Care Act 2012 which, for the first time, creates equal status for mental and physical health across Government and for the NHS and social care.</p><p> </p><p>Since April 2013, gender identity services have been commissioned by NHS England. NHS England will continue to work with the transgendered community, clinical experts and stakeholders through the clinical reference group for gender identity services, to produce a single and consistent policy for the whole of England.</p><p> </p><p>In order to ensure equitable access to services, an England-wide Interim Protocol was consulted on, developed and became operational on 1 November 2013. The Protocol is based on the previously published and well received Scottish Protocol. The Protocol relies on the publication of the Inter-Collegiate “Good practice guidelines for the treatment of adults with gender dysphoria” published at the end of October 2013. A fully consulted policy document and service specifications will be published during 2014.</p><p> </p><p>In addition, NHS England has commissioned a review of transgendered patients' access to the NHS. This review has considered all aspects of access to NHS services and is currently being finalised in readiness for publishing.</p> answering member printed Earl Howe grouped question UIN HL343 question first answered 25/06/2014 12:16:07 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

61925

	registered interest
	date	16/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Gender Recognition
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what action they are taking to support transgenderpeople's mental health and wellbeing.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL343
	answer	answer is ministerial correction date of answer 25/06/2014 answer text <p>We expect people with transgender issues to have the same access to National Health Service treatment, including mental health services, as anybody else in the population. Mental Health has been a priority for this Government for several years now. We made this commitment explicit in the Health and Social Care Act 2012 which, for the first time, creates equal status for mental and physical health across Government and for the NHS and social care.</p><p> </p><p>Since April 2013, gender identity services have been commissioned by NHS England. NHS England will continue to work with the transgendered community, clinical experts and stakeholders through the clinical reference group for gender identity services, to produce a single and consistent policy for the whole of England.</p><p> </p><p>In order to ensure equitable access to services, an England-wide Interim Protocol was consulted on, developed and became operational on 1 November 2013. The Protocol is based on the previously published and well received Scottish Protocol. The Protocol relies on the publication of the Inter-Collegiate “Good practice guidelines for the treatment of adults with gender dysphoria” published at the end of October 2013. A fully consulted policy document and service specifications will be published during 2014.</p><p> </p><p>In addition, NHS England has commissioned a review of transgendered patients' access to the NHS. This review has considered all aspects of access to NHS services and is currently being finalised in readiness for publishing.</p> answering member printed Earl Howe grouped question UIN HL342 question first answered 25/06/2014 12:16:06 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath